Jonathan Rubin
CIK: 0001836067
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
SUPERNUS PHARMACEUTICALS, INC.
Discretionary Trading P&L
Holdings
Transaction History (41 total)
- Oct 30, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Unit
70K shares- - Aug 12, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct363 shares at avg. $46.57$17K - Aug 12, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Exercise(M)Direct750 shares- - Jul 29, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectPerformance Share Unit
750 shares- - Feb 25, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Disposition(D)DirectRestricted Stock Unit
1.3K shares- - Feb 25, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)Direct1.3K shares- - Feb 25, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct675 shares at avg. $50.69$34K - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct369 shares at avg. $50.86$19K - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)Direct1.3K shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct671 shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Disposition(D)DirectRestricted Stock Unit
750 shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)Direct1.1K shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct603 shares at avg. $51.35$31K - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)Direct750 shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Disposition(D)DirectRestricted Stock Unit
1.3K shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Disposition(D)DirectRestricted Stock Unit
1.1K shares- - Feb 18, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Unit
3K shares- - Feb 18, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectEmployee Stock Option (Right to Buy)
13.5K shares- - Sep 25, 2025SUPN
SUPERNUS PHARMACEUTICALS, INC.
Exercise(M)Direct1.9K shares- - Sep 25, 2025SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct840 shares at avg. $46.21$39K - Sep 10, 2025SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectPerformance Share Unit
1.9K shares- - Mar 5, 2025SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct314 shares at avg. $33.05$10K - Mar 5, 2025SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct577 shares at avg. $33.05$19K - Mar 5, 2025SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct577 shares at avg. $33.05$19K - Feb 23, 2025SUPN
SUPERNUS PHARMACEUTICALS, INC.
Disposition(D)DirectRestricted Stock Unit
1.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 30, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Restricted Stock Unit | 70,000 | - | - | Direct |
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 363 | $46.57 | $16,905 | Direct |
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Exercise(M) | 750 | - | $0 | Direct |
| Jul 29, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Performance Share Unit | 750 | - | - | Direct |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Disposition(D) Restricted Stock Unit | 1,250 | - | - | Direct |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) | 1,250 | - | $0 | Direct |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 675 | $50.69 | $34,216 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 369 | $50.86 | $18,767 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) | 1,250 | - | $0 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 671 | - | $0 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Disposition(D) Restricted Stock Unit | 750 | - | - | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) | 1,125 | - | $0 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 603 | $51.35 | $30,964 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) | 750 | - | $0 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Disposition(D) Restricted Stock Unit | 1,250 | - | - | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Disposition(D) Restricted Stock Unit | 1,125 | - | - | Direct |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Restricted Stock Unit | 3,000 | - | - | Direct |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Employee Stock Option (Right to Buy) | 13,500 | - | - | Direct |
| Sep 25, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Exercise(M) | 1,875 | - | - | Direct |
| Sep 25, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 840 | $46.21 | $38,816 | Direct |
| Sep 10, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Performance Share Unit | 1,875 | - | - | Direct |
| Mar 5, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 314 | $33.05 | $10,378 | Direct |
| Mar 5, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 577 | $33.05 | $19,070 | Direct |
| Mar 5, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 577 | $33.05 | $19,070 | Direct |
| Feb 23, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Disposition(D) Restricted Stock Unit | 1,250 | - | - | Direct |
1-25 of 41 transactions
About Rubin Jonathan
Rubin Jonathan (SEC CIK 0001836067) files insider reports with the SEC as SVP, Chief Medical Officer of SUPERNUS PHARMACEUTICALS, INC. (SUPN).
Signal8 holds 14 ownership filings by Rubin Jonathan, all Form 4s, filed between Dec 26, 2024 and Nov 2, 2026. Those filings report 41 transactions, from Dec 23, 2024 to Oct 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Rubin Jonathan's filings is in ROCKVILLE, MD.
Recent filings by Rubin Jonathan
- Oct 30, 2026: Grant or award of SUPN derivative securities (Form 4, code A).
- Aug 12, 2026: Tax withholding of SUPN shares (Form 4, code F).
- Aug 12, 2026: Option exercise of SUPN shares (Form 4, code M).
- Jul 29, 2026: Grant or award of SUPN derivative securities (Form 4, code A).
- Feb 25, 2026: Disposition to issuer transaction of SUPN derivative securities (Form 4, code D).
Other insiders filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN)
- Khattar Jack A., President, CEO
- DEC TIMOTHY C, Senior Vice-President & CFO
- Mottola Frank, SVP, Chief Tech. Ops. Officer
- Horich William Todd, SVP, Commercial Operations
- Bhatt Padmanabh P., Sr. VP of IP, CSO
- Hudson Frederick M., Director